2 months Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates Zacks
Supernus (SUPN) delivered earnings and revenue surprises of 171.79% and 13.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
X